It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Breast cancer (BC) is currently one of the deadliest tumors worldwide. Cancer stem cells (CSCs) are a small group of tumor cells with self-renewal and differentiation abilities and high treatment resistance. One of the reasons for treatment failures is the inability to completely eliminate tumor stem cells. By using the edgeR package, we identified stemness-related differentially expressed genes in GSE69280. Via Lasso-penalized Cox regression analysis and univariate Cox regression analysis, survival genes were screened out to construct a prognostic model. Via nomograms and ROC curves, we verified the accuracy of the prognostic model. We selected 4 genes (PSMB9, CXCL13, NPR3, and CDKN2C) to establish a prognostic model from TCGA data and a validation model from GSE24450 data. We found that the low-risk score group had better OS than the high-risk score group, whether using TCGA or GSE24450 data. A prognostic model including four stemness-related genes was constructed in our study to determine targets of breast cancer stem cells (BCSCs) and improve the treatment effect.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Radio-Oncology, Suzhou, People’s Republic of China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
2 Jining Tumor Hospital, Department of Oncology, Jining, People’s Republic of China (GRID:grid.89957.3a)
3 Jining No. 1 People’s Hospital, Department of Oncology, Jining, People’s Republic of China (GRID:grid.89957.3a)
4 The Affiliated Suzhou Hospital of Nanjing Medical University, Department of General Practice, Suzhou, People’s Republic of China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
5 The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Thyroid and Breast Surgery, Suzhou, People’s Republic of China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
6 The First Affiliated Hospital of Soochow University, Department of Oncology, Suzhou, People’s Republic of China (GRID:grid.429222.d) (ISNI:0000 0004 1798 0228)